By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Tyrogenex, Inc. 

155 Gibbs Street
Suite 427
Rockville  Maryland  20850  U.S.A.
Phone: 301-880-9595 Fax: 301-880-9599


SEARCH JOBS


Tyrogenex is a biopharmaceutical company focused on improving the lives of patients with wet AMD and solid tumors by discovering medicines to help provide additional treatment options. Tyrogenex’s lead compound is X-82.

YEAR FOUNDED:

2006

LEADERSHIP:

CEO: Eric I. Richman

JOBS:

Please click here for Tyrogenex job opportunities.

FOLLOW TYROGENEX:



Key Statistics


Email: info@tyrogenex.com
Ownership: Private

Web Site: Tyrogenex
Employees:
Symbol: 
 









Company News
Tyrogenex Announces Publication Of Phase I Data For X-82 For The Oral Treatment Of Neovascular Age-Related Macular Degeneration In The Journal Of The American Medical Association 6/8/2017 6:36:22 AM
Tyrogenex Completes Patient Enrollment In Its Phase II Trial Of Orally Administered Vorolanib For Wet Age-Related Macular Degeneration 3/9/2017 8:16:16 AM
ASCO2016: Tyrogenex, Inc. Presents Data Informing Phase II And Supporting Potential Efficacy Of X-82 With Everolimus In Patients With Solid Tumors At The ASCO Annual Meeting 2016 6/6/2016 1:21:59 PM
ASCO2016: Tyrogenex, Inc. To Present At The ASCO Annual Meeting 2016 6/1/2016 4:45:55 PM
Tyrogenex, Inc. To Present At The Landmark Venture Forum At The Boca Raton Resort And Club - Boca Raton, FL 2/19/2016 7:00:23 AM
Tyrogenex, Inc. To Present At 18th Annual BIO CEO & Investor Conference 2/3/2016 10:07:22 AM
Tyrogenex, Inc. To Present At 8th Annual Biotech Showcase 1/4/2016 8:42:39 AM
Tyrogenex, Inc. Presents Final Results From Phase 1 Study Of X-82 For Wet AMD At The 2015 Annual American Academy of Ophthalmology Meeting 11/16/2015 7:43:25 AM
Tyrogenex, Inc. Presents At The 14th Annual BIO Investor Forum 10/19/2015 10:24:40 AM
Tyrogenex, Inc. Presents Final Results From Phase I Study Of X-82 For Wet AMD At The 15th EURETINA Congress 9/21/2015 11:39:15 AM
12
//-->